Data as of .
CURE vs RXD: which held to its multiple?
Over three months against its own daily promise, CURE finished 3.0 points short and RXD 1.9 points over.
ETFIQ Decay Resistance Score: RXD scores higher
Did it keep up with its own daily multiple, compounded day by day?
A percentile among the 391 leveraged ETFs, long, over three months. It is a position in a set, not a rating, and neither end of it is a recommendation. All leveraged ETFs ranked by it · How it is computed
Performance, window by window
| Window | Total return | Multiple would give | Difference | |||
|---|---|---|---|---|---|---|
| CURE | RXD | CURE | RXD | CURE | RXD | |
| 1 month | −7.0% | +3.5% | −5.5% | +3.7% | −1.5 pts | −0.1 pts |
| 3 months | +19.5% | −14.7% | +23.9% | −16.0% | −4.4 pts | +1.3 pts |
| 6 months | +25.4% | −19.1% | +34.0% | −22.7% | −8.6 pts | +3.6 pts |
| 1 year | +46.5% | −29.3% | +61.2% | −40.8% | −14.7 pts | +11.5 pts |
| 3 years | +30.8% | −31.2% | +92.7% | −61.8% | −61.9 pts | +30.6 pts |
| Since launch | +2637.9% | −99.2% | not meaningful | not meaningful | not meaningful | not meaningful |
| CURE Direxion Daily Healthcare Bull 3X ETF Aims to return three times the daily move of health care (XLV) | RXD ProShares UltraShort Health Care Aims to return twice the opposite of the daily move of health care (XLV) | |
|---|---|---|
| Issuer | Direxion | ProShares |
| Sets out to return | +3x | -2x |
| On | XLV | XLV |
| Segment | sector | sector |
| Fund returned, 3 months | +19.5% | −14.7% |
| Underlying returned, 3 months | +8.0% | +8.0% |
| What the stated multiple implies, 3 months | +23.9% | −16.0% |
| Difference from stated, 3 months | −4.4 pts | +1.3 pts |
| Fund returned, 1 year or since launch | +46.5% | −29.3% |
| Difference from stated, over that window | −14.7 pts | +11.5 pts |
| Underlying volatility | 19% | 19% |
| Expense ratio | 0.94% | 0.95% |
| Launched | Jun 15, 2011 | Jan 4, 2010 |
CURE in plain words
Three months to Sep 11, 2026: CURE returned +19.5% where its own daily promise gave +22.5%, 3.0 points short. Read the multiple against the whole window instead and +3 times XLV's 8.0% implies +23.9%, which makes CURE look 4.4 points short. 1.4 of that is daily compounding, which happens to any +3 times fund over the same path, and the rest is the fund. CURE aims to return +3 times XLV's move each day, then resets. Over one day it does that. Over longer, the daily results compound, so the total is not +3 times the period's move: in a market that falls and comes back it is reliably less, and in a steady run it can be more. XLV moved at 19% annualized over that window. That is what decides how far the two figures separate: the same fund on a calm underlying and a violent one is a different product.
RXD in plain words
Three months to Sep 11, 2026: RXD returned −14.7% where its own daily promise gave −16.6%, 1.9 points over. Read the multiple against the whole window instead and −2 times XLV's 8.0% implies −16.0%, which makes RXD look 1.3 points over. 0.6 of that is daily compounding, which happens to any −2 times fund over the same path, and the rest is the fund. RXD aims to return -2 times XLV's move each day, then resets. Over longer, the daily results compound, so the total is not -2 times the period's move: in a market that falls and comes back it is reliably less, and in a steady run it can be more.
Questions people ask
- Which came closer to its stated multiple, CURE or RXD?
- Over the window to Sep 11, 2026, CURE finished 4.4 points from what its multiple implies and RXD finished 1.3 points from its own, so RXD came closer. Neither figure predicts the next window: it depends on how much the underlying moves about.
- Are CURE and RXD levered on the same thing?
- Yes. Both are levered on health care, CURE at +3 times and RXD at -2 times the daily move.
- Which one decays faster, CURE or RXD?
- Decay follows how much the underlying moves about. Over this window CURE’s moved at 19% annualized and RXD’s at 19%, so CURE has the rougher ride and, at the same multiple, loses more to compounding.
- Can I hold CURE or RXD for a year?
- Both reset every day, so the multiple in the name applies to a single day and the daily results compound. Over a year the total is not the multiple times the year’s move, and in a market that falls and comes back it is reliably less. ETFIQ makes no recommendation either way.
- Which is cheaper, CURE or RXD?
- CURE charges 0.94% a year and RXD charges 0.95%, so CURE is cheaper. Fees come from each fund's prospectus.
Other comparisons
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, CURE against RXD, data as of Sep 11, 2026. https://etfiq.com/compare/leverage/CURE-RXD Free to use with attribution; the underlying files are at Open data.